Compare NWTG & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWTG | BOLT |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 7.1M |
| IPO Year | 2022 | 2021 |
| Metric | NWTG | BOLT |
|---|---|---|
| Price | $1.11 | $3.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $29.00 |
| AVG Volume (30 Days) | ★ 64.8K | 31.2K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.09 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,135,000.00 | $7,695,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $104.02 | $2,525.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 136.14 | 0.07 |
| 52 Week Low | $0.70 | $3.10 |
| 52 Week High | $1.97 | $7.20 |
| Indicator | NWTG | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 47.24 |
| Support Level | N/A | $3.13 |
| Resistance Level | N/A | $4.34 |
| Average True Range (ATR) | 0.00 | 0.32 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 40.48 |
Newton Golf Co Inc is a technology-forward golf company engaged in designing, manufacturing, and selling performance golf equipment, including premium golf shafts and putters, and focuses on developing technology-driven golf products intended to enhance player performance. The company sells its products through e-commerce, distributors, wholesale customers, including pro-shops at golf courses and off-course retailers, sporting goods retailers, online retailers, third-party distributors, and through Club Champion Golf.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.